Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci.
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
NOVANTRONE. mitoXANTRONE for injection concentrate
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor.
Current and future immunotherapy targets in autoimmune neurology.
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
UCSF Seminar: "Dynamics of Retina Damage in Acute Optic Neuritis"
A case of multiple evanescent white dot syndrome misdiagnosed as optic neuritis: Differential diagnosis for the neurologist.
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Dimethyl Fumarate Inhibits the Nuclear Factor kappaB Pathway in Breast Cancer Cells by Covalent Modification of p65.
Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.
Alemtuzumab for the Treatment of Multiple Sclerosis
PML in a patient treated with fumaric acid.
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion.
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series.
Monoclonal antibodies in MS: mechanisms of action.
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
Interferon beta for secondary progressive multiple sclerosis.

Pages